Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Massachusetts
Clinical trial register · United States · industry-sponsored

Clinical Trials in Massachusetts, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9144 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 16 Oct 2026, 03:16 UTC
9144
Studies in scope
industry-sponsored, all four open statuses
4957
Recruiting now
open to new participants
2196
Lead sponsors
across recruiting studies
Top states
California 152 Florida 150 Arizona 95 Georgia 87 Illinois 69
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca67 Novartis Pharmaceuticals66 Eli Lilly and Company52 AbbVie39 Bristol-Myers Squibb35 Clear sponsor filter
State
California152 Florida150 Arizona95 Georgia87 Illinois69
All 44 states
Target enrolment
to

Trials with a site in Massachusetts

52 of 9144 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Not yet open
Eli Lilly and Company
Phase 2
50
Alabama, California, Florida, Massachusetts, New Jersey, Texas, Virginia, Wisconsin
2026-10
Recruiting
Eli Lilly and Company
Phase 2
120
Alabama, Arizona, California, Florida, Georgia, Illinois, Indiana, Massachusetts
2026-08-27
Recruiting
Eli Lilly and Company
Phase 3
1,000
Alabama, Arizona, California, Florida, Georgia, Illinois, Maryland, Massachusetts
2026-08-14
Recruiting
Eli Lilly and Company
Phase 2
606
Alabama, California, Colorado, Florida, Illinois, Indiana, Massachusetts, Michigan
2026-08-07
Recruiting
Eli Lilly and Company
Phase 3
252
California, Florida, Idaho, Massachusetts, Michigan, Nevada, Pennsylvania, Utah
2026-06-01
Recruiting
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
NCT07101328Lymphoma, Non-Hodgkin, B-cell Lymphoma, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular
Eli Lilly and Company
Phase 1
215
California, Colorado, Connecticut, Illinois, Iowa, Kansas, Massachusetts, Michigan
2026-05-28
Recruiting
A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)
NCT07589595Cognitive Dysfunction, Lewy Body Disease, Synucleinopathies, Amyloid
DrugDonanemab
Eli Lilly and Company
Phase 2
350
Arizona, California, Colorado, Connecticut, Florida, Indiana, Kansas, Massachusetts
2026-05-20
Recruiting
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
NCT07226843Lymphoma, Non-Hodgkin's, Lymphoma, Diffuse Large B-Cell, Follicular Lymphoma
DrugRituximab
Eli Lilly and Company
Phase 1
460
Arizona, California, Colorado, Florida, Georgia, Massachusetts, Minnesota, New York
2026-04-17
Recruiting
Eli Lilly and Company
Phase 2
60
California, Florida, Massachusetts, Michigan, New Hampshire, Texas, Utah
2026-04-14
Recruiting
A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo
NCT07533019Vitiligo, Non-Segmental Vitiligo (NSV)
DrugLY4005130
Eli Lilly and Company
Phase 2
66
Arizona, California, Florida, Georgia, Indiana, Massachusetts, Michigan, New Hampshire
2026-04-14
Recruiting
Eli Lilly and Company
Phase 2
450
Arkansas, California, Connecticut, Florida, Georgia, Illinois, Maryland, Massachusetts
2026-02-10
Recruiting
Eli Lilly and Company
Phase 3
1,000
California, Connecticut, Florida, Georgia, Indiana, Iowa, Maryland, Massachusetts
2026-02-09
Active, closed
Eli Lilly and Company
Phase 3
600
Arizona, California, Florida, Hawaii, Kentucky, Massachusetts, Michigan, New York
2026-01-24
Recruiting
Eli Lilly and Company
Phase 1
41
Connecticut, Massachusetts, Michigan, New York
2025-12-22
Recruiting
Eli Lilly and Company
Phase 2
400
California, Connecticut, Florida, Georgia, Iowa, Maryland, Massachusetts, Pennsylvania
2025-11-24
Recruiting
Eli Lilly and Company
Phase 2
252
Arizona, California, Colorado, Florida, Illinois, Indiana, Kentucky, Massachusetts
2025-11-10
Recruiting
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
NCT07213791Ovarian Neoplasms, Breast Neoplasms, Pancreatic Intraductal Neoplasms, Colorectal Neoplasms
Eli Lilly and Company
Phase 1
241
California, Florida, Indiana, Maryland, Massachusetts, Michigan, Minnesota, Missouri
2025-10-22
Recruiting
Eli Lilly and Company
Phase 2
531
Arizona, California, Colorado, Florida, Illinois, Kentucky, Massachusetts, Nevada
2025-10-22
Recruiting
Eli Lilly and Company
Phase 3
1,100
Arizona, Arkansas, California, Florida, Illinois, Maryland, Massachusetts, New York
2025-10-16
Active, closed
Eli Lilly and Company
Phase 3
800
Arizona, California, Colorado, Connecticut, Georgia, Illinois, Kansas, Massachusetts
2025-09-15
Recruiting
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
NCT07114601Breast Neoplasms, Colorectal Neoplasms, Prostate Neoplasm, Endometrial Neoplasms
Eli Lilly and Company
Phase 1
421
California, Florida, Georgia, Massachusetts, Michigan, Missouri, New York, Pennsylvania
2025-08-06
Recruiting
A Study of LY4175408 in Participants With Advanced Cancer
NCT07046923Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma, Endometrial Neoplasms, Neoplasm Metastasis
DrugsCisplatin·Carboplatin·Pembrolizumab
Eli Lilly and Company
Phase 1
240
California, Florida, Illinois, Indiana, Massachusetts, Missouri, New Jersey, New York
2025-07-28
Active, closed
Eli Lilly and Company
Phase 3
586
Arizona, California, Colorado, Florida, Kansas, Louisiana, Massachusetts, Michigan
2025-05-29
Recruiting
Eli Lilly and Company
Phase 4
279
Florida, Georgia, Illinois, Massachusetts, Minnesota, Nebraska, New York, North Carolina
2025-05-20
Recruiting
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
NCT06876649Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma
DrugPirtobrutinib
Eli Lilly and Company
Phase 4
787
Florida, Georgia, Illinois, Massachusetts, Minnesota, Nebraska, New York, North Carolina
2025-05-20
Active, closed
Eli Lilly and Company
Phase 3
487
Arizona, California, Connecticut, Florida, Hawaii, Maryland, Massachusetts, Michigan
2025-04-30
Active, closed
Eli Lilly and Company
Phase 3
974
Arizona, California, Connecticut, Florida, Hawaii, Maryland, Massachusetts, Michigan
2025-04-30
Active, closed
Eli Lilly and Company
Phase 3
487
Arizona, California, Connecticut, Florida, Hawaii, Maryland, Massachusetts, Michigan
2025-04-30
Recruiting
Eli Lilly and Company
Phase 4
200
Arizona, California, Florida, Georgia, Indiana, Kentucky, Maryland, Massachusetts
2025-03-19
Active, closed
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
NCT06607185Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumor
Drugs5Fluorouracil·Leucovorin·Irinotecan·Cetuximab
Eli Lilly and Company
Phase 1
750
Alabama, Arizona, California, Connecticut, Illinois, Indiana, Massachusetts, Michigan
2024-10-21
Recruiting
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
NCT06561685Metastatic Solid Tumor, Advanced Solid Tumor, Non-small Cell Lung Cancer, SMARCA4-Deficient Tumor
DrugsNab-paclitaxel·Pemetrexed·Paclitaxel·Cisplatin
Eli Lilly and Company
Phase 1
340
California, Colorado, Florida, Illinois, Massachusetts, New York, Ohio, Tennessee
2024-09-19
Recruiting
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
NCT06586515Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer
DrugsLeucovorin·Irinotecan·Cetuximab·Adrucil
Eli Lilly and Company
Phase 1
630
California, Colorado, District of Columbia, Florida, Georgia, Indiana, Massachusetts, Michigan
2024-09-12
Recruiting
Eli Lilly and Company
Phase 1
48
Florida, Georgia, Massachusetts, New Jersey, North Carolina
2024-08-15
Recruiting
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
NCT06465069Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm
Eli Lilly and Company
Phase 1
420
California, Colorado, Florida, Georgia, Illinois, Indiana, Massachusetts, Michigan
2024-07-01
Recruiting
Eli Lilly and Company
Phase 3
90
California, Connecticut, Georgia, Indiana, Massachusetts, New Jersey, New York, Ohio
2024-03-13
Active, closed
A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors
NCT06238479Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm
Eli Lilly and Company
Phase 1
490
Florida, Georgia, Massachusetts, Missouri, New York, Texas
2024-03-05
Recruiting
Gene Therapy Trial for Otoferlin Gene-mediated Hearing Loss
NCT05821959Sensorineural Hearing Loss, Bilateral
Eli Lilly and Company
Phase 3
48
California, Iowa, Massachusetts, Ohio, Pennsylvania, Tennessee
2023-09-15
Recruiting
Eli Lilly and Company
Phase 1/2
880
California, Colorado, Connecticut, Florida, Georgia, Iowa, Louisiana, Massachusetts
2023-04-17
Active, closed
A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)
NCT05738486Alzheimer's Disease, Dementia, Brain Diseases, Central Nervous System Diseases
DrugsDonanemab·Dexamethasone
Eli Lilly and Company
Phase 3
1,175
Arizona, California, Florida, Georgia, Massachusetts, Michigan, New Jersey, Rhode Island
2023-02-28
Active, closed
Eli Lilly and Company
Phase 1
260
Arizona, California, Florida, Georgia, Massachusetts, Minnesota, Missouri, New York
2022-05-11
Active, closed
Eli Lilly and Company
Phase 3
152
California, Florida, Massachusetts, Minnesota, New York, Pennsylvania, Tennessee, Texas
2021-12-20
Active, closed
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
NCT04956640Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Endometrial Neoplasms, Ovarian Neoplasms
DrugsOlomorasib·Erbitux·Cetuximab·Pemetrexed
Eli Lilly and Company
Phase 1/2
540
Alabama, California, Connecticut, Florida, Indiana, Louisiana, Massachusetts, New Hampshire
2021-07-19
Recruiting
A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
NCT04844606Ulcerative Colitis, Ulcerative Colitis Chronic, Inflammatory Bowel Diseases, Crohn's Disease
DrugMirikizumab
Eli Lilly and Company
Phase 3
150
California, Connecticut, Georgia, Massachusetts, Missouri, New York, Pennsylvania, Texas
2021-05-26
Active, closed
Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations
NCT04603001Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia (CMML), Myeloproliferative Neoplasms (MPNs)
DrugsLY3410738·Azacitidine·Venetoclax
Eli Lilly and Company
Phase 1
260
California, Florida, Illinois, Massachusetts, New York, North Carolina, Tennessee, Texas
2020-11-19
Active, closed
Eli Lilly and Company
Phase 1
200
Arizona, California, Florida, Illinois, Indiana, Maryland, Massachusetts, Minnesota
2020-10-01
Active, closed
Eli Lilly and Company
Phase 1
71
California, Colorado, Illinois, Massachusetts, Ohio, Pennsylvania, Texas
2020-06-11
Active, closed
A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer
NCT04188548Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer, Endometrial Cancer
DrugsImlunestrant·Alpelisib·Everolimus·Abemaciclib
Eli Lilly and Company
Phase 1
379
Arizona, Arkansas, California, Florida, Georgia, Indiana, Maryland, Massachusetts
2019-12-10
Active, closed
A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors
NCT03899792Medullary Thyroid Cancer, Infantile Myofibromatosis, Infantile Fibrosarcoma, Papillary Thyroid Cancer
DrugSelpercatinib
Eli Lilly and Company
Phase 1/2
36
California, Colorado, Florida, Massachusetts, Minnesota, New York, Ohio, Pennsylvania
2019-06-13
Active, closed
Eli Lilly and Company
Phase 2/3
393
Arizona, Arkansas, California, Colorado, Florida, Georgia, Indiana, Massachusetts
2018-11-26
Active, closed
Eli Lilly and Company
Phase 1
100
Arkansas, California, Colorado, Massachusetts, Michigan, New York
2016-11-14
Active, closed
Eli Lilly and Company
Phase 3
669
Arkansas, California, Florida, Georgia, Illinois, Maryland, Massachusetts, Michigan
2014-07-22
Active, closed
Eli Lilly and Company
Phase 1
198
Arkansas, California, Massachusetts, Minnesota, New York, North Carolina, Oregon, Pennsylvania
2014-03-10
Rows per page Showing 1–52 of 52
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 16 October 2026. https://priyalifescience.com/clinical-trials-usa/state/massachusetts

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,144 studies in total at the last sync on 16 Oct 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 52 of those studies with a site in Massachusetts that also match the filters currently applied.

How many clinical trials are recruiting in Massachusetts?

30 of the 52 studies on this page are recruiting new participants as of the 16 Oct 2026, 03:16 UTC sync. A further 1 have not yet opened recruitment, 21 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Massachusetts), 52 studies
PhaseStudiesRecruitingShare
Phase 1191036.5%
Phase 316730.8%
Phase 210919.2%
Phase 1/2315.8%
Phase 4335.8%
Phase 2/3101.9%

Most active sponsors

Lead sponsors with the most studies (Massachusetts)
Lead sponsorStudiesRecruiting
Eli Lilly and Company5230
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.